Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.